Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
1. There is a 71% lower risk of disease progression or death in the nirogacestat group than in the placebo...
Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
1. Event-free survival at 2 years was longer in the neoadjuvant-adjuvant group vs the adjuvant-only group (72% vs 49%). 2....
Lobar vs Sublobar Resection for Peripheral Stage IA NSCLC
1. The 5-year disease-free survival, overall survival, and recurrence rates were similar in both lobar vs sublobar resections for patients...
Futibatinib for FGFR2 Mutated Intrahepatic Cholangiocarcinoma
1. Using futibatinib to treat patients with FGFR mutated intrahepatic cholangiocarcinoma resulted in a 42% objective response rate (partial or...
Cisplatin with Veliparib in BRCA Stratified Metastatic Triple-Negative Breast Cancer
1. There was some progression-free survival benefit in adding veliparib to cisplatin in patients who had homologous recombination DNA repair...
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
1. In patients with KRAS p.G12C mutated pancreatic cancer, 21% had a partial response, and 0% had a complete response....
Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma
1 .Tumor-infiltrating lymphocytes therapy shows improvements in PFS when compared to ipilimumab 2. All patients with tumor-infiltrating lymphocytes therapy had...
PD-1 antibody plus chemotherapy in low PD-L1 expressing esophageal squamous cell carcinoma
1. The post-hoc analysis of JUPITER-06 showed the superiority of adding toripalimab (PD-1 antibody) to chemotherapy in patients with advanced...
Overall survival with triplet therapy in BRAF V600 mutation-positive advanced melanoma
1. OS in triplet combination therapy (atezolizumab, vemurafenib, and cobimetinib) while numerally better, was not statistically improved when compared to...
First-line treatment with immune checkpoint inhibitor rather than BRAF and MEK leads to improved survival
1. Starting treatment with nivolumab/ipilimumab rather than dabrafenib/trametinib resulted in an improvement in 2-year overall survival (72% vs 52%) 2....
